GleamWall
中文EN

IRD Opus Genetics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1228627 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-45.9%
TTM net income YoY-100.4%
TTM EPS YoY20.4%
Revenue 3-yr CAGR-48.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-777.7%
Net margin-1,726.7%
FCF margin—
EBITDA margin-776.9%

Returns

ROE-615.6%
ROA-208.0%
ROIC (approx.)—
Asset turnover0.12x

Leverage & solvency

Liabilities / assets59.7%
Debt / equity0.93x
Current ratio9.65x
Interest coverage-217.47x

Cash quality & payout

Operating cash flow / net income0.36x
Accruals ratio-134.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.14M$755,000$2.16M$3.87M$3.08M$2.88M$4.37M$4.30M
R&D expense$14.49M$11.21M$10.58M$10.43M$6.41M$6.02M$7.95M$7.03M
SG&A expense$5.89M$6.03M$5.94M$4.89M$4.98M$5.77M$6.35M$7.30M
Operating income-$19.25M-$16.48M-$14.36M-$11.45M-$8.31M-$8.91M-$9.93M-$38.03M
Interest expense$79,000$74,000$69,000$61,000$68,000$0$0$0
Pretax income-$46.49M-$8.10M-$65.53M-$16.52M-$17.45M-$7.42M-$8.19M-$35.13M
Income tax$0$0$0$0$0$0$0$0
Net income-$46.49M-$8.10M-$65.53M-$16.52M-$17.45M-$7.42M-$8.19M-$35.13M
EBITDA-$19.23M-$16.47M-$14.35M-$11.44M-$8.30M-$8.89M-$9.92M-$38.02M
EPS (basic)-0.46-0.08-0.75—-0.25-0.12-0.24—
EPS (diluted)-0.46-0.14-0.75—-0.25-0.12-0.24—
Weighted avg. shares (diluted)101.84M111.38M86.89M—70.64M63.38M33.88M—
Balance sheet
Cash & equivalents$88.97M$88.81M$59.96M$45.09M$30.82M$32.43M$41.79M$30.32M
Short-term investments———$0$0$0$1,000$2,000
Receivables$1.00M$1.04M$1.73M$2.00M$2.92M$3.40M$3.08M$3.56M
Current assets$94.86M$92.70M$66.60M$50.04M$35.91M$38.44M$47.93M$36.61M
PP&E, net$339,000$172,000$186,000$199,000$212,000$226,000$239,000$252,000
Total assets$95.30M$92.97M$66.79M$50.24M$36.12M$38.66M$48.17M$36.86M
Current liabilities$9.83M$7.61M$9.34M$7.78M$29.09M$20.19M$24.25M$11.29M
Long-term debt$35.65M$35.28M$1.20M$1.13M$1.07M$1.00M—$0
Total debt$35.65M$35.28M$1.20M$1.13M$1.07M$1.00M—$0
Total liabilities$56.86M$105.95M$87.89M$34.90M$30.16M$21.19M$24.25M$11.29M
Shareholders' equity$38.43M-$12.99M-$45.84M$15.35M$5.97M$17.47M$5.07M$6.72M
Net debt-$53.32M-$53.53M-$58.76M-$43.96M-$29.75M-$31.43M—-$30.32M
Shares outstanding95.80M82.65M71.40M69.89M64.54M59.91M45.48M31.57M
Cash flow statement
Operating cash flow-$14.04M-$11.95M-$12.73M-$9.83M-$6.16M-$10.27M-$8.99M-$7.44M
Investing cash flow-$189,000$0$0$0$0$0$0$1.21M
Financing cash flow$14.39M$40.90M$27.59M$24.11M$4.54M$906,000$20.46M-$83,000
Depreciation & amortization$22,000$14,000$13,000$13,000$13,000$14,000$13,000$10,000
Stock-based compensation$1.59M$1.41M$1.46M$774,000$816,000$896,000$913,000$795,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.